Hemangioma, Cavernous, Central Nervous System: Clinical Trials

15 trials for Hemangioma, Cavernous, Central Nervous System, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 4 terminated, 2 recruiting, 2 unknown. 4 Phase 2, 2 Early Phase 1, 1 Not applicable, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Completed 3, Terminated 1
Early Phase 12Not yet recruiting 1, Terminated 1
Not applicable1Terminated 1
Phase 11Completed 1

Follow Hemangioma, Cavernous, Central Nervous System: new trials by email Literature Review of Hemangioma, Cavernous, Central Nervous System trials Research Report on Hemangioma, Cavernous, Central Nervous System

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study
Daratumumab - Cavernous Malformation, Cerebral
Early Phase 1Not yet recruitingBeijing Tiantan Hospital102025-07-012025-06-18
Functional Magnetic Resonance Imaging (fMRI) Vascular Reactivity in Cerebral Cavernous Malformations (CCM)
Hyperventilation and CO2 challenge - Cerebral Cavernous Malformation
Not applicableTerminatedUniversity of New Mexico52023-06-152025-06-11
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
REC-994, Placebo - Cerebral Cavernous Malformation
Phase 2CompletedRecursion Pharmaceuticals Inc.622022-03-172026-10-22
CCM Blood Biomarker Validation Study
CCM Hemorrhagic Panel - Hemorrhagic Stroke, Intracerebral, Cerebral Cavernous Malformation
TerminatedTexas Tech University Health Sciences Center, El Paso122021-01-012023-09-01
Study on Treatment Decision-Making and Prognostic Follow-Up for Untreated Cerebral Cavernous Malformations
Hemangioma, Cavernous, Central Nervous System
RecruitingBeijing Tiantan Hospital12002020-09-012025-07-30
Biomarkers of CASH
observational - Cerebral Cavernous Malformation, Cavernous Angioma
Active not recruitingUniversity of Chicago10402020-05-222025-08-11
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Cavernous Malformation, Cerebral, Cavernous Angioma
Recruitingyuanli Zhao2002019-09-032019-09-04
CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness
CCM, Cavernoma
CompletedUniversity of Chicago1232018-08-202024-06-27
Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial
Atorvastatin, Placebo - Cerebral Cavernous Malformation
Phase 1 / Phase 2CompletedUniversity of Chicago802018-07-172025-08-22
Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation
Propranolol - Cerebral Cavernous Malformation
Phase 2CompletedMario Negri Institute for Pharmacological Research712018-04-112022-02-25
Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation
Propranolol, DNA and RNA Analysis - Cerebral Cavernous Malformations
Phase 2TerminatedSt. Joseph's Hospital and Medical Center, Phoenix42018-01-242024-04-19
Treatments and Outcomes of Untreated Cerebral Cavernous Malformations in CHina.
Surgery, Observation - Cerebral Cavernous Malformations
UnknownFirst Affiliated Hospital of Fujian Medical University20002018-01-012018-03-19
CoHOrt of Cerebral CavernOus maLformATion: multicEnter Prospective Observational Study
Cerebral Cavernous Malformation, Intracerebral Hemorrhage
UnknownSeoul National University Hospital2282016-06-012022-05-12
Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins
Simvastatin - Cavernous Angioma, Familial, Cerebral Cavernous Malformations
Early Phase 1TerminatedUniversity of New Mexico122012-03-012024-03-12
Modifiers of Disease Severity in Cerebral Cavernous Malformations
Cavernous Angioma, Familial, Cerebral Cavernous Malformations
CompletedUniversity of California, San Francisco7892010-04-272026-07-27

Narrower conditions

Hemangioma, Cavernous (3)  ·  Cerebral Cavernous Malformations 2 (1)  ·  Cerebral Cavernous Malformations 3 (1)  ·  Cerebral Hemorrhage (1)  ·  Epilepsy (1)  ·  Hemangioma, Capillary (1)  ·  Hemorrhagic Stroke (1)  ·  Seizures (1)

Broader conditions

Brain Diseases (15)  ·  Cardiovascular Abnormalities (15)  ·  Cardiovascular Diseases (15)  ·  Cavernous Sinus Syndromes (15)  ·  Central Nervous System Diseases (15)  ·  Central Nervous System Vascular Malformations (15)  ·  Congenital Abnormalities (15)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15)  ·  Hemangioma (15)  ·  Hematologic Diseases (15)  ·  Hemic and Lymphatic Diseases (15)  ·  Hemorrhagic Disorders (15)  ·  Hemostatic Disorders (15)  ·  Neoplasms (15)  ·  Neoplasms by Histologic Type (15)

Interventions

Propranolol (2)  ·  Atorvastatin (1)  ·  DNA (1)  ·  Observation (1)  ·  Simvastatin (1)  ·  Surgical Procedures, Operative (1)  ·  Watchful Waiting (1)  ·  daratumumab (1)

Sponsors

University of Chicago (3)  ·  Beijing Tiantan Hospital (2)  ·  University of New Mexico (2)  ·  First Affiliated Hospital of Fujian Medical University (1)  ·  Mario Negri Institute for Pharmacological Research (1)  ·  Recursion Pharmaceuticals Inc. (1)  ·  Seoul National University Hospital (1)  ·  St. Joseph's Hospital and Medical Center, Phoenix (1)  ·  Texas Tech University Health Sciences Center, El Paso (1)  ·  University of California, San Francisco (1)  ·  yuanli Zhao (1)

Countries

United States (9)  ·  China (4)  ·  Italy (1)  ·  South Korea (1)

Top investigators

Issam A Awad, MD (2)  ·  Issam Awad, MD (2)  ·  Blaine Hart, MD (1)  ·  Daniel F Hanley, MD (1)  ·  Daniel Hanley, MD (1)  ·  Dezhi Kang, MD,PHD (1)  ·  Elisabetta Dejana, Professor (1)  ·  Helen Kim, MPH, PhD (1)  ·  Helen Kim, PhD (1)  ·  JeongEun Kim, MD. PhD. (1)  ·  Joseph Zabramski, MD (1)  ·  Jun Zhang (1)  ·  Kelly Flemming, MD (1)  ·  Leslie A Morrison, MD (1)  ·  Li Ma, MD, PhD (1)

Results publications

PMID 19833796, PMID 24323376, PMID 24401931, PMID 25472749, PMID 25556204, PMID 25565562, PMID 26795600, PMID 28318403, PMID 28387823, PMID 28489816, PMID 28534135, PMID 30140608, PMID 31643041, PMID 31776290, PMID 31825263, PMID 32100472, PMID 32398113, PMID 32461638, PMID 32467184, PMID 32467778, PMID 32951540, PMID 33122314, PMID 33469662, PMID 34389651, PMID 34479577, PMID 34491620, PMID 36403580, PMID 36695309, PMID 37333396, PMID 38134265, PMID 38134268, PMID 38419711, PMID 40120614, PMID 40175401, PMID 40570636, PMID 40614265, PMID 40899314, PMID 41117517, PMID 41608890

NIH funding

U54NS065705 (2), 2017 (1), R01NS114552 (1), U01NS104157 (1)